A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients

Clinical trial NCT03720366 · COMPLETED

Trial details

NCT number: NCT03720366
Sponsor: Celgene
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Leukemia, Myeloid, Acute

Start date: 2018-10-04
Primary completion: 2023-09-22
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.